Trial site
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
Porto Alegre, 90110-270, BrazilNot linked to an institution yet
- 12running trials
- 2closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 22 trials
- Status
- Active, not recruiting8 trials
- Recruiting3 trials
- Completed1 trial
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Pfizer7 trials
- Agenus Inc.2 trials
- Boehringer Ingelheim1 trial
- Eli Lilly and Company1 trial
- Gilead Sciences1 trial
- and 2 more
Running trials
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Active, not recruiting
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
NCT05909397· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044· Phase 2· Agenus Inc.· Source
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Pfizer· Source
Active, not recruiting
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· Phase 3· Pfizer· Source
Active, not recruiting
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· Phase 3· Gilead Sciences· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Recruiting
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait
NCT05000697· Hospital Alemão Oswaldo Cruz· Source
Contact: Rafael Dutra Vila
Active, not recruiting
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT02763566· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error